Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jama.2018.6923 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combination Immunotherapy with Vaccine and Oncolytic HSV Virotherapy Is Time Dependent.
Mol Cancer Ther
September 2024
Division of Pediatric Hematology and Oncology, Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, Alabama.
Oncolytic virotherapy or immunovirotherapy is a strategy that utilizes viruses to selectively infect and kill tumor cells while also stimulating an immune response against the tumor. Early clinical trials in both pediatric and adult patients using oncolytic herpes simplex viruses (oHSV) have demonstrated safety and promising efficacy; however, combinatorial strategies designed to enhance oncolysis while also promoting durable T-cell responses for sustaining disease remission are likely required. We hypothesized that combining the direct tumor cell killing and innate immune stimulation by oHSV with a vaccine that promotes T cell-mediated immunity may lead to more durable tumor regression.
View Article and Find Full Text PDFPositioning SUMO as an immunological facilitator of oncolytic viruses for high-grade glioma.
Front Cell Dev Biol
October 2023
Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Article Synopsis
- Oncolytic viral (OV) therapies are a new treatment option for hard-to-treat cancers like glioblastoma in the central nervous system but face challenges in effectiveness due to delivery issues and immune responses.
- The SUMO pathway, which regulates various physiological processes, plays a role in both CNS cancers and viral interactions, making it a target for enhancing OV treatments.
- The authors provide an overview of the SUMO pathway's impact on CNS malignancies, the current status of OV therapies, and how the SUMO pathway interacts with the viral lifecycle and immune responses.
Focused Ultrasound Thalamotomy for Tremor in Parkinson's Disease: Outcomes in a Large, Prospective Cohort.
Mov Disord
October 2023
Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Background: Magnetic resonance guided focused ultrasound (MRgFUS) is United States Food and Drug Administration approved for the treatment of tremor-dominant Parkinson's disease (TdPD), but only limited studies have been described in practice.
Objectives: To report the largest prospective experience of unilateral MRgFUS thalamotomy for the treatment of medically refractory TdPD.
Methods: Clinical outcomes of 48 patients with medically refractory TdPD who underwent MRgFUS thalamotomy were evaluated.
Clinical advances in oncolytic virotherapy for pediatric brain tumors.
Pharmacol Ther
November 2022
Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address:
Malignant brain tumors constitute nearly one-third of cancer diagnoses in children and have recently surpassed hematologic malignancies as the most lethal neoplasm in the pediatric population. Outcomes for children with brain tumors are unacceptably poor and current standards of care-surgical resection, chemotherapy, and radiation-are associated with significant long-term morbidity. Oncolytic virotherapy has emerged as a promising immunotherapy for the treatment of brain tumors.
View Article and Find Full Text PDFTumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword.
Int J Mol Sci
February 2022
Harvard Medical School, Boston, MA 02115, USA.
Oncolytic virotherapy is a rapidly progressing field that uses oncolytic viruses (OVs) to selectively infect malignant cells and cause an antitumor response through direct oncolysis and stimulation of the immune system. Despite demonstrated pre-clinical efficacy of OVs in many cancer types and some favorable clinical results in glioblastoma (GBM) trials, durable increases in overall survival have remained elusive. Recent evidence has emerged that tumor-associated macrophage/microglia (TAM) involvement is likely an important factor contributing to OV treatment failure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!